biostudies-literatureLyden PNINDS NIH HHS2888-2895https://www.ebi.ac.uk/biostudies/studies/S-EPMC5134910biostudies-literatureUnknown47(12)<h4>Background and purpose</h4>Therapeutic hypothermia is a potent neuroprotectant approved for cerebral protection after neonatal hypoxia-ischemia and cardiac arrest. Therapeutic hypothermia for acute ischemic stroke is safe and feasible in pilot trials. We designed a study protocol to provide safer, faster therapeutic hypothermia in stroke patients.<h4>Methods</h4>Safety procedures and 4°C saline infusions for faster cooling were added to the ICTuS trial (Intravascular Cooling in the Treatment of Stroke) protocol. A femoral venous intravascular cooling catheter after intravenous recombinant tissue-type plasminogen activator in eligible patients provided 24 hours cooling followed by a 12-hour rewarm. Serial safety assessments and imaging were performed. The primary end point was 3-month mStrokeResults of the ICTuS 2 Trial (Intravascular Cooling in the Treatment of Stroke 2).PMC5134910P50 NS044148P50 NS044227Shah QErnstrom KJanis SWilson JHerial NTanner AMarcolini EGMcBee DOddo MMalik AKhanolkar PBrautigam RBruce NSuys TJain SSohdi ACordier MMoy CNeil WMullin ADietrich DOvbiagele BGilmore EJWilsom CLewandowski CLin FKhanna ARzesiewicz TStern BWijman CKim EHamilton SLundell AMerenda AJasak SDugan GYenari MKelly NHolzer EShushrutha Hedna VEscobar APoisson SBussinger PEdwards NJGreer DKelley CRosado CRaman RHeim LPiantadosi BMcCullough LChamorro ALittle ASimpson JO'Phelan KGrotta JRapp KAlexandrov ARemillard SAgarwal SSchlick KGuzik ARutledge NWarren SBroessner GChavez RBrown DSchmutzhard EHussain SJonczak KBerry SVelazquez AParker SMeyer BModir RMeyer DSisson AJurf JSo JSLewis PJane Hess MJimenez-Maggiora GAltafullah IAlbright KDiringer MMichel PJones WConcha MFalo CHemmen THess MJBecker KKizza RTafreshi GRoldan AMuranevici GSong SEscioglou EDerdeyn CCollaboratorsPerez Barcena JCruz-Flores SSmith CTorretta SShell EMiller JBDirnagl UEskandari ALyden PMayer SClaassen JBrown RfalseResults of the ICTuS 2 Trial (Intravascular Cooling in the Treatment of Stroke 2).<h4>Background and purpose</h4>Therapeutic hypothermia is a potent neuroprotectant approved for cerebral protection after neonatal hypoxia-ischemia and cardiac arrest. Therapeutic hypothermia for acute ischemic stroke is safe and feasible in pilot trials. We designed a study protocol to provide safer, faster therapeutic hypothermia in stroke patients.<h4>Methods</h4>Safety procedures and 4°C saline infusions for faster cooling were added to the ICTuS trial (Intravascular Cooling in the Treatment of Stroke) protocol. A femoral venous intravascular cooling catheter after intravenous recombinant tissue-type plasminogen activator in eligible patients provided 24 hours cooling followed by a 12-hour rewarm. Serial safety assessments and imaging were performed. The primary end point was 3-month m2016-01-01T00:00:00Z2016 Dec2025-04-22T01:45:36.722Z2019-03-27T02:30:36ZS-EPMC51349102783474210.1161/STROKEAHA.116.01420010.1161/strokeaha.116.014200